<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02587624</url>
  </required_header>
  <id_info>
    <org_study_id>PMUN-DB-002-MAGNA-AF</org_study_id>
    <nct_id>NCT02587624</nct_id>
  </id_info>
  <brief_title>Remote MAGNetic Catheter Ablation for Atrial Fibrillation</brief_title>
  <acronym>MAGNA-AF</acronym>
  <official_title>Safety, Radiation Exposure and Efficacy of Remote MAGNetic Catheter Ablation for Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paracelsus Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Paracelsus Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective observational single center trial, evaluating the safety, radiation exposure and&#xD;
      efficacy of remote magnetic catheter ablation for atrial fibrillation in daily routine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Since the first description in 1998 catheter-interventional ablation (CA) has&#xD;
      evolved to a standard treatment for symptomatic drug-refractory atrial fibrillation (AF).&#xD;
&#xD;
      Ablation efficacy but also complication percentage and radiation exposure are influenced by&#xD;
      several factors, among them patient age, body weight, type and duration of AF, underling&#xD;
      cardiac disease as well as the used ablation method, technology and the experience of the&#xD;
      operator.&#xD;
&#xD;
      The objectives of developing a system for remote magnetic catheter navigation (RMN) were to&#xD;
      improve the efficacy and safety of complex ablation procedures and to reduce radiation&#xD;
      exposure. However, convincing data supporting this theory are still lacking.&#xD;
&#xD;
      Aim: To evaluate efficacy, safety profile / complication rate and radiation exposure in&#xD;
      serial ablation procedures for paroxysmal and persistent AF as well as repeat interventions&#xD;
      based on remote magnetic navigation and 3-D image integration with assessment of the learning&#xD;
      curve for this complex technology.&#xD;
&#xD;
      Design: single center observational registry, analytical questioning, non-randomized,&#xD;
      non-controlled, not blinded, consecutive patient inclusion&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Inclusion criteria: Consecutive patients with class I or class IIa indication for CA for&#xD;
      symptomatic atrial fibrillation according to the current guidelines.&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  Contraindication for AF catheter ablation&#xD;
&#xD;
        -  Contraindication for RMN procedure. (These patients may undergo AF ablation with another&#xD;
           technology, e.g. cryo-balloon ablation).&#xD;
&#xD;
        -  Age &lt; 18 years, gravidity&#xD;
&#xD;
      Endpoints Primary endpoint&#xD;
&#xD;
      Safety:&#xD;
&#xD;
        -  The number of peri-procedural major complications.&#xD;
&#xD;
        -  Adverse events are classified according to the 2012 Expert consensus statement on&#xD;
           catheter and surgical ablation of AF [Calkins H et al. 2012 HRS/EHRA/ECAS Expert&#xD;
           Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation. Europace&#xD;
           (2012) 14, 528-606 doi:10.1093/europace/eus027].&#xD;
&#xD;
      Secondary endpoints Efficacy&#xD;
&#xD;
        -  Acute: number of successfully isolated pulmonary veins.&#xD;
&#xD;
        -  Mid-term: freedom from any atrial tachyarrhythmia (atrial fibrillation/atypical atrial&#xD;
           flutter/atrial tachycardia; duration &gt; 30 sec) after 6 months follow-up (initial&#xD;
           blanking period of 3 months).&#xD;
&#xD;
        -  Long-term:&#xD;
&#xD;
        -  Freedom from any atrial tachyarrhythmia (duration &gt; 30 sec) after 12 months follow-up&#xD;
           (initial blanking period of 3 months).&#xD;
&#xD;
        -  Time to first recurrence of an atrial tachyarrhythmia after an initial blanking period&#xD;
           of 3 months.&#xD;
&#xD;
      Radiation exposure:&#xD;
&#xD;
        -  mean effective dose (ED), based on the measured dose-area-product. Aim is to show the&#xD;
           potential of RMN to reduce the mean ED below 1.5 mSv in daily routine RMN AF ablation&#xD;
           procedures&#xD;
&#xD;
        -  The fluoroscopy parameters are documented for system calibration (A), transseptal&#xD;
           access/catheter positioning (B), mapping/ablation (C).&#xD;
&#xD;
      Safety:&#xD;
&#xD;
        -  Number of peri-procedural minor complications&#xD;
&#xD;
        -  Number of all procedure-related complications during 12 months follow-up.&#xD;
&#xD;
      Subgroups:&#xD;
&#xD;
        -  Type of AF (paroxysmal versus non-paroxysmal)&#xD;
&#xD;
        -  Type of antiarrhythmic drug treatment (AAD)&#xD;
&#xD;
        -  Demonstration of low-voltage areas / fibrosis&#xD;
&#xD;
        -  Ablation: only pulmonary vein antral isolation (PVAI) versus additional substrate&#xD;
           modification / box isolation of fibrotic areas (BIFA)&#xD;
&#xD;
        -  Adipositas (BMI ≥ 30 kg/m²)&#xD;
&#xD;
        -  Transseptal access after puncture versus via patent foramen ovale&#xD;
&#xD;
        -  First ablation versus repeat procedure&#xD;
&#xD;
      Randomisation: none&#xD;
&#xD;
      Study procedure:&#xD;
&#xD;
      Pre-ablation: screening of all patients, referred for catheter ablation for AF. Inclusion&#xD;
      after given informed consent. Oral anticoagulation (OAC) for at least 3 weeks.&#xD;
      Transesophageal echocardiography (TEE) in all patients.&#xD;
&#xD;
      Ablation: Non-interrupted OAC, non-vitamin-K antagonist treatment withheld only the morning&#xD;
      before ablation. All patients undergo PVAI and mapping for fibrotic areas, additional&#xD;
      substrate modification on decision of the operator.&#xD;
&#xD;
      Techniques and technologies used: RMN: Niobe/Epoch®, Navigant™, 0.1 Tesla, Stereotaxis Inc.;&#xD;
      fluoroscopy system: Siemens AXIOM-Artis VC12B, 6-1 fps; non-fluoroscopic mapping (NFM):&#xD;
      Carto-RMT, magnetic resonance-image-integration, (Biosense-Webster Inc.); TEE-guided single&#xD;
      transseptal puncture, &quot;Single catheter ablation&quot; technique: Navistar-RMT Thermocool&#xD;
      (Biosense-Webster Inc.), target temperature 48°C, power limit 40Watts (posterior left atrial&#xD;
      wall) up to 50W, irrigation infusion rate 17 mL/min; Heparin for maintaining an activated&#xD;
      clotting time between 300 to 400 sec. Endpoint: bidirectional PV-block.&#xD;
&#xD;
      Post-ablation in hospital: OAC continued immediately following sheath removal after ablation&#xD;
      for a minimum of 2 months, thereafter according to embolic risk (CHA2DS2-VASc-risk&#xD;
      evaluation). 48 hours telemonitoring, echocardiography.&#xD;
&#xD;
      Follow up: blanking period 3 months. Clinical evaluation after 3, 6 and 12 months including&#xD;
      echocardiography and 72-hours Holter.&#xD;
&#xD;
      Unscheduled visits for complications and symptoms suggesting recurrent tachyarrhythmia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Safety: peri-procedural major complications.</measure>
    <time_frame>Peri-procedural (from the beginning of the procedure until 48 hours after sheath removal)</time_frame>
    <description>Procedure associated adverse events are classified according to the 2012 Expert consensus statement on catheter and surgical ablation of AF [Calkins et al, Europace 2012].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute efficacy: number of successfully isolated pulmonary veins.</measure>
    <time_frame>Intra-procedural</time_frame>
    <description>Number of successfully isolated pulmonary veins.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term efficacy: freedom from atrial tachyarrhythmia.</measure>
    <time_frame>12 months</time_frame>
    <description>- Freedom from any atrial tachyarrhythmia (AF/flutter/atrial tachycardia; duration &gt; 30 sec, initial blanking period of 3 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term efficacy: time to recurrence of atrial tachyarrhythmia.</measure>
    <time_frame>12 months</time_frame>
    <description>- Time to first recurrence of any atrial tachyarrhythmia (AF/flutter/atrial tachycardia; duration &gt; 30 sec) after an initial blanking period of 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: radiation exposure.</measure>
    <time_frame>Peri-procedural (from the beginning of the procedure until sheath removal)</time_frame>
    <description>mean effective dose (ED), based on the measured dose-area-product. Aim is to show the potential of RMN to reduce the mean ED below 1.5 mSv in daily routine RMN AF ablation procedures&#xD;
The fluoroscopy parameters are documented for system calibration (A), transseptal access/catheter positioning (B), mapping/ablation (C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: peri-procedural minor complications.</measure>
    <time_frame>Peri-procedural (from the beginning of the procedure until 48 hours after sheath removal)</time_frame>
    <description>Procedure related adverse events are classified according to the 2012 Expert consensus statement on catheter and surgical ablation of AF [Calkins et al, Europace 2012].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: incidence of procedure related adverse events during long term follow-up.</measure>
    <time_frame>12 months</time_frame>
    <description>Any complication during follow-up. Procedure related adverse events are classified according to the 2012 Expert consensus statement on catheter and surgical ablation of AF [Calkins et al, Europace 2012].</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Efficacy: freedom from atrial tachyarrhythmia in pre-specified patient subgroups.</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from any atrial tachyarrhythmia (AF/flutter/atrial tachycardia; duration &gt; 30 sec, initial blanking period of 3 months) in different subgroups:&#xD;
Type of AF (paroxysmal versus non-paroxysmal)&#xD;
Type of antiarrhythmic drug treatment&#xD;
Demonstration of low-voltage areas / fibrosis&#xD;
Ablation: only pulmonary vein antral isolation (PVAI) versus additional substrate modification / box isolation of fibrotic areas (BIFA)&#xD;
Adipositas (BMI ≥ 30 kg/m²)&#xD;
Transseptal access after puncture versus via patent foramen ovale&#xD;
First ablation versus repeat procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Efficacy: time to first recurrence of atrial tachyarrhythmia in pre-specified patient subgroups.</measure>
    <time_frame>12 months</time_frame>
    <description>Time to first recurrence of any atrial tachyarrhythmia (AF/flutter/atrial tachycardia; duration &gt; 30 sec) after an initial blanking period of 3 months in different subgroups:&#xD;
Type of AF (paroxysmal versus non-paroxysmal)&#xD;
Type of antiarrhythmic drug treatment&#xD;
Demonstration of low-voltage areas / fibrosis&#xD;
Ablation: only pulmonary vein antral isolation (PVAI) versus additional substrate modification / box isolation of fibrotic areas (BIFA)&#xD;
Adipositas (BMI ≥ 30 kg/m²)&#xD;
Transseptal access after puncture versus via patent foramen ovale&#xD;
First ablation versus repeat procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety: procedure related complications in pre-specified subgroups during long term follow-up.</measure>
    <time_frame>12 months</time_frame>
    <description>Number of procedure associated complications in different subgroups:&#xD;
Type of AF (paroxysmal versus non-paroxysmal)&#xD;
Type of antiarrhythmic drug treatment&#xD;
Demonstration of low-voltage areas / fibrosis&#xD;
Ablation: only pulmonary vein antral isolation (PVAI) versus additional substrate modification / box isolation of fibrotic areas (BIFA)&#xD;
Adipositas (BMI ≥ 30 kg/m²)&#xD;
Transseptal access after puncture versus via patent foramen ovale&#xD;
First ablation versus repeat procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Radiation exposure in pre-specified patient subgroups.</measure>
    <time_frame>Intra-procedural (duration of procedure)</time_frame>
    <description>Procedural radiation exposure in different subgroups:&#xD;
Type of AF (paroxysmal versus non-paroxysmal)&#xD;
Demonstration of low-voltage areas / fibrosis&#xD;
Ablation: only pulmonary vein antral isolation (PVAI) versus additional substrate modification / box isolation of fibrotic areas (BIFA)&#xD;
Adipositas (BMI ≥ 30 kg/m²)&#xD;
Transseptal access after puncture versus via patent foramen ovale&#xD;
First ablation versus repeat procedure</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>RMN AF ablation</arm_group_label>
    <description>Consecutive patients with class I or class IIa indication for catheter ablation for symptomatic atrial fibrillation according to the current guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>catheter ablation</intervention_name>
    <description>Intervention: All patients undergo magnetically guided pulmonary vein antral isolation and mapping for fibrotic areas. Procedural endpoint: bidirectional PV block. Additional substrate modification on decision of the operator.</description>
    <arm_group_label>RMN AF ablation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients with class I or class IIa indication for catheter ablation for&#xD;
        symptomatic atrial fibrillation according to the current guidelines [Camm AJ et al. 2012&#xD;
        focused update of the ESC guidelines for the management of atrial fibrillation. European&#xD;
        Heart Journal (2012) 33, 2719-2747].&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consecutive patients with class I or class IIa indication for catheter ablation for&#xD;
             symptomatic atrial fibrillation according to the current guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication for AF catheter ablation&#xD;
&#xD;
          -  Contraindication for magnetically guided ablation procedure&#xD;
&#xD;
          -  Age &lt; 18 years, gravidity, breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Bastian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum Fuerth, Fuerth</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Paracelsus Medical University, Klinikum Nürnberg</name>
      <address>
        <city>Nuremberg</city>
        <state>Bavaria</state>
        <zip>90471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Bastian D, Schwab J, Steurer KT, Brinker-Paschke A, Boessenecker A, Doering R, Karakurt Z, Vitali-Serdoz L, Pauschinger M, Göhl K. Oesophageal injury following magnetically guided single-catheter ablation for atrial fibrillation: insights from the MAGNA-AF registry. Europace. 2018 May 1;20(suppl_2):ii48-ii55. doi: 10.1093/europace/euy021.</citation>
    <PMID>29722860</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 18, 2015</study_first_submitted>
  <study_first_submitted_qc>October 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <last_update_submitted>January 9, 2021</last_update_submitted>
  <last_update_submitted_qc>January 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Paracelsus Medical University</investigator_affiliation>
    <investigator_full_name>Dr. Dirk Bastian</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>catheter ablation</keyword>
  <keyword>remote magnetic navigation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

